Drugs / HEC169096
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05451602 | Oct 2022 → Dec 2026 expected | neoplasm | Sunshine Lake Pharma Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HEC169096 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05451602 ↗ |
| Action | Inhibit | “Highly-selective RET Inhibitor” NCT05451602 ↗ |
| Route | Oral | “Oral dose of HEC169096 as determined during Phase 2.” NCT05451602 ↗ |
| Target | RET | “Highly-selective RET Inhibitor” NCT05451602 ↗ |